22.02.2023 | Original Article
Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer
Itsuki Yuasa, Masatsugu Hamaji, Hiroaki Ozasa, Yuichi Sakamori, Hironori Yoshida, Yojiro Yutaka, Toshi Menju, Toyohiro Hirai, Hiroshi Date
General Thoracic and Cardiovascular Surgery
Einloggen, um Zugang zu erhalten
Immune checkpoint inhibitors (ICIs) are effective treatment options for patients with advanced non-small cell lung cancer (NSCLC); however, there is a dearth of data on outcomes of patients receiving ICIs for postoperative recurrence. The objective of this study was to investigate the short- and long-term outcomes of patients who received ICIs for postoperative recurrence.
A retrospective chart review was performed to identify consecutive patients who received ICIs for postoperative recurrence of NSCLC. We investigated therapeutic responses, adverse events, progression-free survival (PFS), and overall survival (OS). Survival outcomes were estimated using the Kaplan–Meier method. Univariable and multivariable analyses were performed using the Cox proportional hazards model.
Eighty-seven patients, with a median age of 72 years were identified between 2015 and 2022. The median follow-up period after ICI initiation was 13.1 months. Adverse events of grade ≥ 3 were observed in 29 (33.3%) patients, including 17 (19.5%) patients with immune-related adverse events. The median PFS and OS of the whole cohort were 3.2 and 17.5 months, respectively. Limited to those receiving ICIs as first-line therapy, the median PFS and OS were 6.3 and 25.0 months, respectively. On multivariable analysis, smoking history (HR: 0.29, 95% CI 0.10–0.83) and non-squamous cell histology (HR: 0.25, 95% CI 0.11–0.57) were associated with more favorable PFS in patients receiving ICIs as first-line treatment.
Outcomes in patients receiving ICIs as first-line treatment appear acceptable. A multi-institutional study is required to confirm our findings.